Sex, Timing, and Outcomes of Curative-Intent Immunotherapy
Anne-Murielle Hollinger, Camille L. Gerard, Victoria J. Andreas, Zayne M. Roa Diaz et autres
0 citationsJAMA Network Open
Swiss Group For Clinical Cancer Research
Bern · CH · nonprofit
1616Publications signalées
223026Citations signalées
12Thèmes principaux
Principaux domaines
Lymphoma Diagnosis and TreatmentBreast Cancer Treatment StudiesLung Cancer Treatments and MutationsCancer Treatment and PharmacologyCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchColorectal Cancer Treatments and StudiesLung Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchImmunotherapy and Immune ResponsesEstrogen and related hormone effectsImmune Cell Function and Interaction
Évolution annuelle
Publications récentes
Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial
Ilaria Colombo, Pascale C. S. Rietveld, Stefanie Fischer, Stefania Merlo et autres
0 citationsCancer Chemotherapy and Pharmacology
OA02.2. Survival Comparison in Patients With Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Satoru Matsuda, Jun Okui, Kengo Nagashima, Yasunori Sato et autres
0 citationsDiseases of the Esophagus
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial
Marco Ladetto, Katja Gutmair, Rita Tavarozzi, Alexandra Pawlikowski et autres
0 citationsJournal of Clinical Oncology
Impact of Postoperative Antithrombotic Treatment on Patency and Survival After Open Posterior Popliteal Artery Aneurysm Repair: A Multicenter Retrospective Cohort Analysis from the PARADE Study
Giorgio Prouse, Giulia Bertagna, F Andréoli, Maria Antonella Ruffino et autres
0 citationsJournal of Clinical Medicine
Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14)
Yannik Da Silva, Dapi Menglin Chiang, Laura Benecke, Michael W. Pfaffl et autres
0 citationsFrontiers in Immunology
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
P.A. Francis, O. Pagani, G. F. Fleming, B. A. Walley et autres
1 citationAnnals of Oncology
CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemia
Rathana Kim, Marie Passet, Hugo Bergugnat, Loïc Vasseur et autres
0 citationsHemaSphere
Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19
Richard Cathomas, Ulf Petrausch, Stefanie Hayoz, Martin Spahn et autres
1 citationJournal of Clinical Oncology
NoLEEta: No chemotherapy in intermediate-risk HR+ HER2− early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.
F C Bidard, Thomas Bachelot, Alexia Savignoni, Jerome Martin Babau et autres
0 citationsJournal of Clinical Oncology
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma—SAKK 66/18 Trial
Maria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi, Urban Novak et autres
0 citationsCancers
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors: A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients (SAKK 66/17).
Markus Joerger, Kira‐Lee Koster, Enrique Alejandre-Lafont, Patrick Knuesel et autres
0 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.